Radius Health got its osteoporosis drug FDA approved in 2017 — and still filed for Chapter 11 in 2022 because the commercial launch never paid back the 440 million dollars spent developing it.
Evaluating only Radius Health’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
Radius Health founded
DOWN ROUND
Down round or bridge financing
SHUTDOWN
Bankruptcy: Radius Health ceases operations
Full Analysis
Free · no account needed
Documented cause
Radius Health won FDA approval for abaloparatide (Tymlos) for osteoporosis in 2017, a genuine scientific achievement. But the drug entered a crowded market dominated by generics and Lilly existing drug, and sales never reached the level needed to service the company debt load. Commercial expenses outpaced revenue, debt came due, and Radius filed for Chapter 11 in August 2022, selling assets for approximately 27 million dollars.
Lesson
“FDA approval is necessary but not sufficient — a drug entering a crowded indication at premium price must have a credible payer reimbursement strategy before commercial launch.”